|Mr. Teofilo David Raad||Pres, CEO & Director||472.55k||N/A||1970|
|Mr. William E. Duke Jr.||CFO, Treasurer & Sec.||465.12k||N/A||1972|
|Dr. Robert S. Langer Jr.||Founder & Member of Scientific Advisory Board||N/A||N/A||1949|
|Prof. David A. Edwards||Founder & Member of Scientific Advisory Board||N/A||N/A||1961|
|Dr. Alexander M. Klibanov||Founder||N/A||N/A||1950|
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Pulmatrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.